Design of novel cyclic altered peptide ligands of myelin basic protein MBP83-99 that modulate immune responses in SJL/J mice

Journal of Medicinal Chemistry

Volumn 51, Issue 13, 2008, Pages 3971-3978

  Katsara, Maria ^a,b   Deraos, George ^b   Tselios, Theodore ^b   Matsoukas, John ^b   Apostolopoulos, Vasso ^a  

^a BURNET INSTITUTE   (Australia)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; INTERLEUKIN 4; MANNAN; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN[83-99]; T LYMPHOCYTE RECEPTOR;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BINDING SITE; CONTROLLED STUDY; CYCLIZATION; CYTOKINE RELEASE; DRUG DESIGN; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; MOUSE; MULTIPLE SCLEROSIS; MYELIN SHEATH; NONHUMAN; SWISS JAMES LAMBERT MOUSE; TH2 CELL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; CELL PROLIFERATION; CELLS, CULTURED; CYCLIZATION; DRUG DESIGN; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-4; LIGANDS; MICE; MOLECULAR SEQUENCE DATA; MUTATION; MYELIN BASIC PROTEINS; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; T-LYMPHOCYTES;

EID: 46849118301     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8000554     Document Type: Article

References (39)

1. Steinman, L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 1996, 85, 299-302.
2. Ota, K.; Matsui, M.; Milford, E. L.; Mackin, G. A.; Weiner, H. L.; Hafler, D. A. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990, 346, 183-187.
3. Martin, R.; McFarland, H. F.; McFarlin, D. E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 1992, 10, 153-187.
4. Krogsgaard, M.; Wucherpfennig, K. W.; Cannella, B.; Hansen, B. E.; Svejgaard, A.; Pyrdol, J.; Ditzel, H.; Raine, C.; Engberg, J.; Fugger, L. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J. Exp. Med. 2000, 191, 1395-1412.
5. Steinman, L.; Waisman, A.; Altmann, D. Major T-cell responses in multiple sclerosis. Mol. Med. Today 1995, 1, 79-83.
6. Bieganowska, K. D.; Ausubel, L. J.; Modabber, Y.; Slovik, E.; Messersmith, W.; Hafler, D. A. Direct ex vivo analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease. J. Exp. Med. 1997, 185, 1585-1594.
7. Moreau, T.; Coles, A.; Wing, M.; Isaacs, J.; Hale, G.; Waldmann, H.; Compston, A. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996, 119 (Part 1), 225-237.
8. Willenborg, D. O.; Staykova, M. A. Cytokines in the pathogenesis and therapy of autoimmune encephalomyelitis and multiple sclerosis. Adv. Exp. Med. Biol. 2003, 520, 96-119.
9. Pette, M.; Fujita, K.; Wilkinson, D.; Altmann, D. M.; Trowsdale, J.; Giegerich, G.; Hinkkanen, A.; Epplen, J. T.; Kappos, L.; Wekerle, H. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 7968-7972.
10. Martin, R.; Jaraquemada, D.; Flerlage, M.; Richert, J.; Whitaker, J.; Long, E. O.; McFarlin, D. E.; McFarland, H. F. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J. Immunol. 1990, 145, 540-548.
11. Wucherpfennig, K. W.; Sette, A.; Southwood, S.; Oseroff, C.; Matsui, M.; Strominger, J. L.; Hafler, D. A. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J. Exp. Med. 1994, 179, 279-290.
12. Wucherpfennig, K. W.; Zhang, J.; Witek, C.; Matsui, M.; Modabber, Y.; Ota, K.; Hafler, D. A. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J. Immunol. 1994, 152, 5581-5592.
13. Gauthier, L.; Smith, K. J.; Pyrdol, J.; Kalandadze, A.; Strominger, J. L.; Wiley, D. C.; Wucherpfennig, K. W. Expression and crystallization of the complex of HLA-DR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin basic protein. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 11828-11833.
14. Smith, K. J.; Pyrdol, J.; Gauthier, L.; Wiley, D. C.; Wucherpfennig, K. W. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J. Exp. Med. 1998, 188, 1511-1520.
15. Wucherpfennig, K. W.; Hafler, D. A.; Strominger, J. L. Structure of human T-cell receptors specific for an immunodominant myelin basic protein peptide: positioning of T-cell receptors on HLA-DR2/peptide complexes. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 8896-8900.
16. Li, Y.; Huang, Y.; Lue, J.; Quandt, J. A.; Martin, R.; Mariuzza, R. A. Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J. 2005, 24, 2968-2979.
17. Bhardwaj, V.; Kumar, V.; Grewal, I. S.; Dao, T.; Lehmann, P. V.; Geysen, H. M.; Sercarz, E. E. T cell determinant structure of myelin basic protein in B10.PL, SJL/J, and their FlS. J. Immunol. 1994, 152, 3711-3719.
18. Greer, J. M.; Sobel, R. A.; Sette, A.; Southwood, S.; Lees, M. B.; Kuchroo, V. K. Immunogenic and encephalitogenic epitope clusters of myelin proteolipid protein. J. Immunol. 1996, 156, 371-379.
19. Rudensky, A.; Preston-Hurlburt, P.; al-Ramadi, B. K.; Rothbard, J.; Janeway, C. A., Jr. Truncation variants of peptides isolated from MHC class II molecules suggest sequence motifs. Nature 1992, 359, 429-431.
20. Kappos, L.; Comi, G.; Panitch, H.; Oger, J.; Antel, J.; Conlon, P.; Steinman, L. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat. Med. 2000, 6, 1176-1182.
21. Crowe, P. D.; Qin, Y.; Conlon, P. J.; Antel, J. P. NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients. Ann. Neurol. 2000, 48, 758-765.
22. Bielekova, B.; Goodwin, B.; Richert, N.; Cortese, I.; Kondo, T.; Afshar, G.; Gran, B.; Eaton, J.; Antel, J.; Frank, J. A.; McFarland, H. F.; Martin, R. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 2000, 6, 1167-1175.
23. Katsara, M.; Tselios, T.; Deraos, S.; Deraos, G.; Matsoukas, M. T.; Lazoura, E.; Matsoukas, J.; Apostolopoulos, V. Round and round we go: cyclic peptides in disease. Curr. Med. Chem. 2006, 13, 2221-2232.
24. Matsoukas, J.; Apostolopoulos, V.; Kalbacher, H.; Papini, A. M.; Tselios, T.; Chatzantoni, K.; Biagioli, T.; Lolli, F.; Deraos, S.; Papathanassopoulos, P.; Troganis, A.; Mantzourani, E.; Mavromoustakos, T.; Mouzaki, A. Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators. J. Med. Chem. 2005, 48, 1470-1480.
25. Moore, G. J. Discovery and design of peptide mimetics. Proc. West. Pharmacol. Soc. 1997, 40, 115-119.
26. Tselios, T.; Probert, L.; Daliani, I.; Matsoukas, E.; Troganis, A.; Gerothanassis, I. P.; Mavromoustakos, T.; Moore, G. J.; Matsoukas, J. M. Design and synthesis of a potent cyclic analogue of the myelin basic protein epitope MBP72-85: importance of the Ala81 carboxyl group and of a cyclic conformation for induction of experimental allergic encephalomyelitis. J. Med. Chem. 1999, 42, 1170-1177.
27. Tselios, T.; Daliani, I.; Deraos, S.; Thymianou, S.; Matsoukas, E.; Troganis, A.; Gerothanassis, I.; Mouzaki, A.; Mavromoustakos, T.; Probert, L.; Matsoukas, J. Treatment of experimental allergic encephalomyelitis (EAE) by a rationally designed cyclic analogue of myelin basic protein (MBP) epitope 72-85. Bioorg. Med. Chem. Lett. 2000, 10, 2713-2717.
28. Tselios, T.; Apostolopoulos, V.; Daliani, I.; Deraos, S.; Grdadolnik, S.; Mavromoustakos, T.; Melachrinou, M.; Thymianou, S.; Probert, L.; Mouzaki, A.; Matsoukas, J. Antagonistic effects of human cyclic MBP(87-99) altered peptide ligands in experimental allergic encephalomyelitis and human T-cell proliferation. J. Med. Chem. 2002, 45, 275-283.
29. Sheng, K. C.; Pouniotis, D. S.; Wright, M. D.; Tang, C. K.; Lazoura, E.; Pietersz, G. A.; Apostolopoulos, V. Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology 2006, 118, 372-383.
30. Apostolopoulos, V.; Pietersz, G. A.; Loveland, B. E.; Sandrin, M. S.; McKenzie, I. F. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 10128-10132.
31. Apostolopoulos, V.; Pietersz, G. A.; McKenzie, I. F. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 1996, 14, 930-938.
32. Lofthouse, S. A.; Apostolopoulos, V.; Pietersz, G. A.; Li, W.; McKenzie, I. F. Induction of T1 (cytotoxic lymphocyte) and/or T2 (antibody) responses to a mucin-1 tumour antigen. Vaccine 1997, 15, 1586-1593.
33. Kappos, L.; Polman, C. H.; Freedman, M. S.; Edan, G.; Hartung, H. P.; Miller, D. H.; Montalban, X.; Barkhof, F.; Bauer, L.; Jakobs, P.; Pohl, C.; Sandbrink, R. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006, 67, 1242-1249.
34. Kappos, L.; Traboulsee, A.; Constantinescu, C.; Eralinna, J. P.; Forrestal, F.; Jongen, P.; Pollard, J.; Sandberg-Wollheim, M.; Sindic, C.; Stubinski, B.; Uitdehaag, B.; Li, D. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006, 67, 944-953.
35. Barlos, K.; Gatos, D.; Koutsogianni, S. Fmoc/Trt-amino acids: comparison to Fmoc/tBu-amino acids in peptide synthesis. J. Pept. Res. 1998, 51, 194-200.
36. Barlos, K.; Gatos, D. 9-Fluorenylmethyloxycarbonyl/ tbutyl-based convergent protein synthesis. Biopolymers 1999, 51, 266-278.
37. Tselios, T.; Daliani, I.; Probert, L.; Deraos, S.; Matsoukas, E.; Roy, S.; Pires, J.; Moore, G.; Matsoukas, J. Treatment of experimental allergic encephalomyelitis (EAE) induced by guinea pig myelin basic protein epitope 72-85 with a human MBP(87-99) analogue and effects of cyclic peptides. Bioorg. Med. Chem. 2000, 8, 1903-1909.
38. Apostolopoulos, V.; Karanikas, V.; Haurum, J. S.; McKenzie, I. F. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J. Immunol. 1997, 159, 5211-5218.
39. Tselios, T. V.; Lamari, F. N.; Karathanasopoulou, I.; Katsara, M.; Apostolopoulos, V.; Pietersz, G. A.; Matsoukas, J. M.; Karamanos, N. K. Synthesis and study of the electrophoretic behavior of mannan conjugates with cyclic peptide analogue of myelin basic protein using lysine-glycine linker. Anal. Biochem. 2005, 347, 121-128.